Elevation Oncology, Inc. (ELEV)

NASDAQ: ELEV · IEX Real-Time Price · USD
2.640
-0.030 (-1.12%)
At close: Jul 19, 2024, 4:00 PM
2.770
+0.130 (4.92%)
After-hours: Jul 19, 2024, 7:47 PM EDT
-1.12%
Market Cap 144.25M
Revenue (ttm) n/a
Net Income (ttm) -39.35M
Shares Out 54.64M
EPS (ttm) -0.98
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 441,244
Open 2.650
Previous Close 2.670
Day's Range 2.620 - 2.780
52-Week Range 0.363 - 5.830
Beta 1.40
Analysts Strong Buy
Price Target 7.80 (+195.46%)
Earnings Date Aug 1, 2024

About ELEV

Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company’s lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 25, 2021
Employees 29
Stock Exchange NASDAQ
Ticker Symbol ELEV
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for ELEV stock is "Strong Buy." The 12-month stock price forecast is $7.8, which is an increase of 195.46% from the latest price.

Price Target
$7.8
(195.46% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Elevation Oncology Announces Planned Combination Strategy for EO-3021 in Patients with Gastric or Gastroesophageal Junction Cancer

-- Plan to evaluate EO-3021 in combination with ramucirumab and dostarlimab; entered into clinical supply agreements with Lilly and GSK, respectively -- -- Expect to initiate dosing in combination por...

23 days ago - PRNewsWire

Elevation Oncology to Present at the Citizens JMP Life Sciences Conference

BOSTON , May 7, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients ac...

2 months ago - PRNewsWire

Elevation Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Achievements

-- Enrollment ongoing in Phase 1 clinical trial of EO-3021 in the U.S. and Japan; expect to announce initial safety and efficacy data by mid-3Q 2024, with additional data in 1H 2025 -- -- Presented pr...

2 months ago - PRNewsWire

Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024

-- On-track to nominate development candidate in 2024 -- BOSTON, April 8, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and deve...

3 months ago - PRNewsWire

Elevation Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Achievements

--Expanded ongoing Phase 1 clinical trial of EO-3021 globally, dosing first patient in Japan; on track to provide update in mid-2024 and to report additional data in 1H 2025 -- -- Preclinical proof-of...

4 months ago - PRNewsWire

Elevation Oncology to Present Preclinical Proof-of-Concept Data for HER3-ADC Program at the American Association for Cancer Research (AACR) Annual Meeting 2024

-- Data support ongoing development of antibody-drug conjugate (ADC) program targeting HER3-expressing cancers – -- On-track to nominate development candidate in 2024 -- BOSTON , March 5, 2024 /PRNews...

4 months ago - PRNewsWire

Elevation Oncology Appoints Experienced Clinical Development Leaders Julie Cherrington, Ph.D. and Alan Sandler, M.D.

BOSTON , March 4, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients ...

4 months ago - PRNewsWire

SHAREHOLDER ALERT: Kaskela Law LLC Announces Shareholder Investigation of Elevation Oncology (ELEV) and Encourages Investors to Contact the Firm

PHILADELPHIA , Feb. 29, 2024 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Elevation Oncology, Inc. (NYSE: ELEV) on behalf of the company's investors. The investigation seeks to d...

5 months ago - PRNewsWire

Elevation Oncology to Participate in Upcoming Investor Conferences

BOSTON , Feb. 28, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients ...

5 months ago - PRNewsWire

Elevation Oncology Expands Ongoing Phase 1 Clinical Trial of EO-3021 Globally, Dosing First Patient in Japan

-- On track to provide update from ongoing Phase 1 clinical trial in mid-2024; additional data expected in 1H 2025 -- BOSTON , Feb. 22, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an...

5 months ago - PRNewsWire

Elevation Oncology Announces Appointment of Darcy Mootz, Ph.D., to its Board of Directors

BOSTON , Jan. 22, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients ...

6 months ago - PRNewsWire

Elevation Oncology Announces Program Updates and Upcoming 2024 Milestones

-- Update from Ongoing Phase 1 Clinical Trial of EO-3021 Now Expected Mid-2024 -- -- Expanding EO-3021 Clinical Development Program to Include Combination Strategy --  -- Announcing HER3-targeting ADC...

7 months ago - PRNewsWire

Elevation Oncology to Present at the Piper Sandler 35th Annual Healthcare Conference

BOSTON , Nov. 22, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients ...

8 months ago - PRNewsWire

Elevation Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Business Achievements

-- Enrollment is ongoing in the Phase 1 clinical trial evaluating EO-3021 in patients with advanced solid tumors likely to express Claudin 18.2; preliminary safety and anti-tumor activity data expecte...

9 months ago - PRNewsWire

Elevation Oncology to Present at the H.C. Wainwright 25th Annual Global Investment Conference

NEW YORK , Sept. 5, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patient...

11 months ago - PRNewsWire

Elevation Oncology Announces First Patient Dosed in the Phase 1 Clinical Trial Evaluating EO-3021

NEW YORK, Aug. 16, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients...

1 year ago - PRNewsWire

Elevation Oncology Reports Second Quarter 2023 Financial Results and Highlights Recent Business Achievements

Initial Phase 1 SYSA1801 (EO-3021) data presented by partner CSPC Pharmaceutical Group Limited at ASCO 2023 showed promising signs of efficacy, including a 47.1% ORR in patients with resistant/refract...

1 year ago - PRNewsWire

Elevation Oncology Appoints Joseph Ferra as Chief Executive Officer and Promotes Tammy Furlong to Chief Financial Officer

NEW YORK , July 13, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patient...

1 year ago - PRNewsWire

Elevation Oncology Announces Pricing of $50 Million Public Offering

NEW YORK , June 8, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients...

1 year ago - PRNewsWire

Elevation Oncology Announces Launch of Proposed Public Offering

NEW YORK , June 8, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients...

1 year ago - PRNewsWire

Elevation Oncology Highlights First-in-Human Phase 1 SYSA1801 (EO-3021) Clinical Data to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023

Initial data showed promising signs of efficacy, including a 47.1% ORR in patients with resistant/refractory gastric cancer expressing Claudin 18.2, with a well-tolerated safety profile Elevation Onco...

1 year ago - PRNewsWire

Elevation Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Business Achievements

Partner CSPC Pharmaceutical Group Limited's ongoing Phase 1 SYSA1801 (EO-3021) clinical trial data selected for poster presentation and poster discussion at ASCO 2023 Presented EO-3021 preclinical pro...

1 year ago - PRNewsWire

Elevation Oncology Highlights Clinical Data for SYSA1801 (EO-3021) to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023

NEW YORK , April 26, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patien...

1 year ago - PRNewsWire

Elevation Oncology Presents EO-3021 Preclinical Proof-of-Concept Data and Highlights a Clinical Case Study in Claudin 18.2-Expressing Cancers at AACR 2023

NEW YORK, April 17, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patient...

1 year ago - PRNewsWire

Elevation Oncology to Present at the American Association of Cancer Research (AACR) Annual Meeting 2023

- Company plans to highlight preclinical proof-of-concept data for EO-3021 in an oral presentation at the New Drugs on the Horizon special session  NEW YORK , March 14, 2023 /PRNewswire/ -- Elevation ...

1 year ago - PRNewsWire